Exome Asset Management’s Akero Therapeutics AKRO Stock Holding History

Exome Asset Management’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-58,579	Closed	-$2.78M	–	62
2025 Q3	$2.78M	Buy	+58,579	New	+$2.84M	1.68%	24
2025 Q2	–	Sell	-76,379	Closed	-$3.47M	–	65
2025 Q1	$3.09M	Buy	76,379 +7,771	+11%	+$329K	2.75%	12
2024 Q4	$1.91M	Sell	68,608 -8,492	-11%	-$257K	1.43%	30
2024 Q3	$2.21M	Buy	+77,100	New	+$2.01M	1.5%	30

Other funds holding AKRO

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Exome Asset Management's AKRO Position: Q4 2025 in Review

Exome Asset Management sold out of Akero Therapeutics (AKRO) in Q4 2025, closing a stake of 58,579 shares — an estimated $2.78M sold.

Exome Asset Management first reported a position in AKRO in Q3 2024 and held it in 4 quarters. The position peaked at $3.09M in Q1 2025. 2 funds tracked by Wall St. Rank hold AKRO as of Q4 2025.

Exome Asset Management reported no remaining Akero Therapeutics position as of Q4 2025 after selling out during the quarter.
Exome Asset Management sold 58,579 Akero Therapeutics shares in Q4 2025, an estimated $2.78M.
Exome Asset Management first reported a position in Akero Therapeutics in Q3 2024 and held it in 4 quarters.
Exome Asset Management's Akero Therapeutics position peaked at $3.09M in Q1 2025.
2 funds tracked by Wall St. Rank held Akero Therapeutics as of Q4 2025.

Based on Exome Asset Management's 13F filing for Q4 2025, filed 13 Feb 2026.